AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms

Rhea-AI Summary

Applied Genetic Technologies Corporation (AGTC), a biotech company focused on gene therapies for rare diseases, announced participation in the Cantor Fitzgerald virtual panel on October 28, 2020, at 10:00 a.m. ET. CEO Sue Washer and VP Dave Knop will discuss key elements of gene therapy manufacturing and AGTC's proprietary processes. The panel will highlight company catalysts over the next year. AGTC is advancing clinical programs for inherited retinal diseases, leveraging its AAV technology for unmet clinical needs in various disorders.

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Executive Officer, and Dave Knop, PhD, Vice President, Process Development and Manufacturing, will participate in the Cantor Fitzgerald “Key Considerations for Gene Therapy Manufacturing and Platforms” virtual panel at 10:00 a.m. ET on Wednesday, October 28, 2020.

The panel will focus on the critical components and capabilities to gene therapy manufacturing, including a discussion on AGTC’s proprietary manufacturing processes associated with AAV, and key company catalysts expected over the next 12 months. The call will be moderated by Kristen Kluska, Biotechnology Research Analyst of Cantor Fitzgerald.

Presentation Information:
Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
Date: Wednesday, October 28, 2020
Time: 10:00 a.m. – 11:30 a.m. ET

To register for the event, please click here.

About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

 

FAQ

What is the purpose of the AGTC panel on October 28, 2020?

The AGTC panel will discuss key considerations in gene therapy manufacturing and company catalysts over the next year.

Who will represent AGTC at the Cantor Fitzgerald panel?

Sue Washer, President & CEO, and Dave Knop, VP of Process Development and Manufacturing, will represent AGTC.

What time does the AGTC panel start on October 28, 2020?

The AGTC panel starts at 10:00 a.m. ET on October 28, 2020.

What topics will be covered in AGTC's panel discussion?

The discussion will cover critical components of gene therapy manufacturing and AGTC's proprietary manufacturing processes.

What is the main focus of AGTC's research?

AGTC focuses on developing gene therapies for rare inherited diseases, particularly in ophthalmic and CNS disorders.